A Phase 3 interventional study of Pemetrexed plus Pembrolizumab and Pembrolizumab in Lung Cancer, sponsored by Hunan Province Tumor Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.
Sponsored by Hunan Province Tumor Hospital · Phase 3, Interventional, and Treatment
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Step 1: All the lung cancer patients treated with Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy were enrolled in this study.
Step 2: All the adverse events were evaluated by principal investigator. Step 3: All the blood and FFPE samples were collected for further anaysis. Step 4: Correlation between adverse events and gene profile was analysis. Step 4: Predict model was construted with AI.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 12,000 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hunan Province Tumor Hospital is the lead sponsor of 72 studies on the registry; 47 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Any conditions can not match for the Inclusion Criteria, includign do not have the data to perform Adverse Events evalutation.
Lung Cancer patients treated with Chemotherapy plus Immune Checkpoint Inhibitors.
Drug: Pemetrexed plus Pembrolizumab
Lung Cancer patients treated with Immune Checkpoint Inhibitors monotherapy.
Drug: Pembrolizumab
Lung Cancer patients treated with Chemotherapy.
Drug: Pemetrexed
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
Also known as: Bevacizumab
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
Also known as: Bevacizumab
Correlation between Adverse events (AEs) and gene profile
Correlation between Adverse events (AEs) and gene profile
Time frame: Time from first subject dose to study completion, or up to 36 month
Adverse events (AEs) rate according to CTCAE 5.0
Adverse events (AEs) rate according to CTCAE 5.0
Time frame: Time from first subject dose to study completion, or up to 36 month
Correlation between Adverse events (AEs) and survival outcome
Correlation between Adverse events (AEs) and survival outcome
Time frame: Time from first subject dose to study completion, or up to 36 month
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hunan Province Tumor Hospital